Systematic literature review evaluates treatment outcomes in patients with refractory metastatic colorectal cancer, suggesting improved survival with FTD/TPI plus bevacizumab.
Key Points
This analysis aims to evaluate the relative efficacy of treatment regimens for patients with refractory metastatic colorectal cancer.
Conducted a systematic literature review and network meta-analysis.
Reviewed randomized controlled trials for treatments in refractory mCRC patients.
Utilized random- and fixed-effects models to assess overall survival and progression-free survival outcomes.
Identified 28 randomized controlled trials for refractory mCRC treatments.
FTD/TPI plus bevacizumab showed statistically significant improvement in overall survival compared to other regimens.
FTD/TPI plus bevacizumab outperformed treatments like cetuximab, regorafenib, and fruquintinib in terms of overall survival and progression-free survival.